pharmaceuticals

Mid-Week Update 01-06-10

The much ballyhooed healthcare legislation continues to meander its way through Washington, seemingly getting watered down at every turn. As the House and Senate versions are reconciled, investors are getting a better idea of what kind of changes to expect in the final package. We will try to steer clear of political arguments in this column, and focus more on investment implications. Read more...

Looking Good: Allergan Gets the Vision Thing Right

It leads in eye health care and controls Botox, two sure growth areas

 
You can make a lot of money investing in health care stocks—but only if you focus on those that tap into long-term trends. These are the ones that will see their revenues and profits soar year after year.
 
For instance, don’t buy a drug company whose main product line is antibiotics, no matter how vital and life-saving, because people use antibiotics only for those short periods when they are sick, and there’s no reason to think there will be a great and steady surge in their use. Instead, find a company that makes the drugs that people use chronically, day in and day out, and that ever larger numbers of people will be demanding.
 
Two of the surest long-term health-related trends are rising longevity—i.e., an aging population—and, sad to say, obesity. People are living longer, and they’re getting fatter. As we explain below, these trends, together, relate to a third trend: the fast-growing incidence of eye disease. Drug companies with a franchise in the eye health area will have many years of torrid growth ahead.
Read more...

A Media/Education Leader, Generic Drugs

Our new picks profit from rapid growth in two different age categories

 
We are selling one stock and buying two others. The net result: a portfolio better attuned to demographic trends and lighter in financial services, an area slated to become more vulnerable as the economic cycle progresses and interest rate hikes grow more likely.
 
Our sale is Bank of New York (reported on our web site). We still like the company, and at some point it could make its way back into our portfolio. We’re selling only because there are even better opportunities elsewhere, not because we’ve lost faith in the company’s underlying fundamentals.
 
Our two additions are the Washington Post (discussed last issue in Sector Sense) and Teva Pharmaceuticals. Both are strong beneficiaries of the demographic trends presented in the preceding article.
Read more...

Let’s Hear it for Health

Strong vital signs for a drug benefits manager and a hearing care provider

 
We love buying growth industries, or growth stocks, when they’re out of favor. By holding onto them patiently, you ultimately benefit from growth in earnings and expanding P/Es alike as Wall Street falls in love with the stocks all over again.
 
Right now, with investors busy chasing technology stocks, health care is being spurned. But health care is an undeniable growth area: people are living longer, baby boomers are aging, and pharmaceuticals and various medical products are becoming ever more technologically sophisticated.
 
One stock positioned to benefit is MIM Corp., a pharmacy benefit management (PBM) and specialty pharmaceutical company that partners with managed care organizations and health care providers to control pre-scription drug costs.
Read more...

More Potent Drug Stocks, A Low-P/E Financial Giant

Plus the lowdown on our risk ratings

 
As we note in our Front Page article, we are dropping Universal Health Services and Eli Lilly from our Growth Portfolio. (We may buy Lilly again once the patent suit against its biggest drug is resolved—in fact, a large drop in the stock if Lilly loses could be a great buying opportunity.) We’re replacing them with biotech gem Genzyme and Walgreen, the nation’s largest pharmacy chain and third-largest retailer.
 
Walgreen (also in our Fund Finds Portfolio) is a big beneficiary of the shift to generic drugs. Generics are great for retailers because their higher margins more than offset the lower selling price. While prescription pharmaceuticals are the core of Walgreen’s business, the company’s stores carry mass merchandise and off-the-shelf drugs as well. Walgreen has been gaining market share in all areas, a sure portent that its 28-year string of rising revenues and earnings will continue well into the future.
Read more...

Poised to Outperform

A diversified group of big-cap dynamos that are cheaper than the S&P 500

 
The past four and a half years have been rough ones for growth investors. Since 1999 the S&P 500 has dropped by more than 10 percent, while purer measures of big cap growth such as the Russell 1000 have shed more than 25 percent. During that same period, though, as readers who have followed me from Personal Finance may know, the growth portfolio I constructed and tracked in that letter, while it took its lumps from time to time, gained 10 percent.
 
In other words, we survived, we kept your capital intact, and a bit better. But we’re not resting on our laurels. In the years ahead, while we don’t foresee another massive bear market, we do expect a great deal of turbulence that will make the kinds of gains chalked up so easily in the 1980’s and 1990’s continue to seem like a distant dream. Meanwhile, increasing numbers of investors approaching retirement face an urgent need to grow their nest eggs. Our work is clearly cut out for us.
Read more...

WHY THE BEST DRUGS ARE BAD FOR BUSINESS 07-02-07

Official, core inflation continues to look rosy and supportive of stocks. Last week we asked the question, “When will the Fed acknowledge that non-core items, food and energy, are definite contributors to inflation?” The answer matters, because such an acknowledgement could be the trigger that sends the market into a trading range.

Right now, the Fed is getting off easy because they only pay heed to core inflation. And core inflation has been well behaved. However, if you add in food and energy, total inflation is running at around 5.5%, which is disturbingly high and certainly takes all the appeal out of buying bonds.

For that reason, we expect the small current rally in bonds will be over soon and that bond prices will be heading lower. We are not chasing this bond rally, and we will not be buying bonds anytime soon.

Instead, at the risk of sounding contrarian, we expect to see a big move upwards in gold prices in the coming months. Summer is usually the weakest period for gold, the time when bottoms are made. So we aren’t concerned about the metal’s limp performance lately. Keep in mind that when gold does make its big moves they tend to be dramatic, giving handsome rewards to those who bought low.Read more...